Monday, 22 Jan 2018

Unknown content type

AASM Guidelines for Sleep Apnea Testing

A task force from the American Academy of Sleep Medicine (AASM) performed a systematic review of the scientific literature on obstructive sleep apnea and screening tests.

2017 Update of Treat to Target Recommendations for SpA/PsA

A 2017 international committee of experts met to assess and revise its earlier 2012 recommendations regarding treating to target in patients with psoriatic arthritis (PsA) and axial peripheral spondyloarthritis (SpA). 

Why TNF Inhibitors May Work in Some Autoinflammatory Patients

The NLRP3 inflammasome is a critical component of the innate immune system and activation of NLRP3 inflammasome results in caspase-1–dependent secretion of the proinflammatory cytokines IL-1β and IL-18. Gain-of-function missense mutations in NLRP3 is thought to drive many of the autoinflammatory diseases, especially the cryopyrin-associated periodic syndromes (CAPS).

The RheumNow Week in Review - 8 December 2017

Dr. Jack Cush covers the news and journal articles published on RheumNow.comin the past week.

Knee Surgery Outcomes Worse with Low Education

Reuters reports that patients who live in low-income communities and lack a college education may have worse pain after knee replacement surgery than their more educated neighbors, citing results from a recent study from the Hospital for Special Surgery in NY.

Infliximab Does Not Increase Perioperative Infection

Staying on a TNF inhibitor (TNFi) throughout major surgery has generatlly been associated with higher rates of perioperative infection (https://buff.ly/2iBFVjp).  On the other hand, discontinuation of the TNFi prior to surgery is associated with lower rates of  infection (https://buff.ly/2iAFZQf)

Rheumatology Year in Review

During 2017, the improvements and refinements seen during previous years in the treatment of rheumatoid arthritis have been extending to other conditions ranging from psoriatic arthritis to lupus and for both monoclonal antibodies and oral small molecule medications.

Advances for Biologics

Do JAK Inhibitors Increase the Risk of Venous Thromboembolic Events?

Drug Safety has published a systematic review of the FDA’s Adverse Event Reporting System (FAERS) and finds numerous reports of thromboembolic adverse events (AEs) associated with two currently marketed Janus kinase (JAK) inhibitors, tofacitinib (Xeljanz) and ruxolitinib (Jakafi). (Citation source: https://buff.ly/2zXyY2X)

PRECISION Subanalyses Question Aspirin Use

The PRECISION trial reported last year that celecoxib appears to be safer than the NSAIDs naproxen or ibuprofen in treating osteoarthritis (OA) and rheumatoid arthritis patients who are at increased cardiovascular risk. New data suggests that adding aspirin may nullify this advantage, according to a study presented at the annual American Heart Association meeting and reported by Medscape.

Fibromyalgia Diagnosed by Two Simple Tests

Researchers from the Oregon Health Science Center have reported that fibromyalgia can be distinguished from chronic pain by primary care providers (PCPs) who employ two simple screening tests: BP cuff-evoked pain and a single patient question, and pain induced by pinching the Achilles tendon. 

Ixekizumab (Taltz) FDA Approved for Psoriatic Arthritis

On Friday, December 1st, the FDA approved Lilly's drug Taltz (ixekizumab) for use in adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. 

Taltz, an IL-17 inhibitor, has previously been approved for plaque psoriasis where it has shown high level PASI75 and PASI100 responses.

The ACR17 RheumNow Week in Review - 1 December 2017

Dr Jack Cush reviews nighlights and news from the past 2 weeks on RheumNow.com. This week's report includes new drug approvals, disappointing ACR guidelines, Lyme & Zika, infertility, dermatomyositis skin outcomes and myositis-associated cancer testing.